from its patent cliff and margins grow. • Best-in-class pipeline. Exceptional data on new oncology portfolio puts AZ in a strong position despite MYSTIC failure. - Expectations for the overall survival readout of MYSTIC in 1H18 are low, so this is close to a free option in our view. A positive would